CA2931396C - An anti-tau antibody for treating tauopothy - Google Patents

An anti-tau antibody for treating tauopothy Download PDF

Info

Publication number
CA2931396C
CA2931396C CA2931396A CA2931396A CA2931396C CA 2931396 C CA2931396 C CA 2931396C CA 2931396 A CA2931396 A CA 2931396A CA 2931396 A CA2931396 A CA 2931396A CA 2931396 C CA2931396 C CA 2931396C
Authority
CA
Canada
Prior art keywords
tau
antibody
amino acid
seq
ipn002
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2931396A
Other languages
English (en)
French (fr)
Other versions
CA2931396A1 (en
Inventor
Irene Griswold-Prenner
Graham Parry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
iPierian Inc
Original Assignee
iPierian Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by iPierian Inc filed Critical iPierian Inc
Publication of CA2931396A1 publication Critical patent/CA2931396A1/en
Application granted granted Critical
Publication of CA2931396C publication Critical patent/CA2931396C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2931396A 2013-11-27 2014-11-25 An anti-tau antibody for treating tauopothy Active CA2931396C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361909965P 2013-11-27 2013-11-27
US61/909,965 2013-11-27
PCT/US2014/067360 WO2015081085A2 (en) 2013-11-27 2014-11-25 Methods of treating a tauopathy

Publications (2)

Publication Number Publication Date
CA2931396A1 CA2931396A1 (en) 2015-06-04
CA2931396C true CA2931396C (en) 2022-09-06

Family

ID=52232410

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2931396A Active CA2931396C (en) 2013-11-27 2014-11-25 An anti-tau antibody for treating tauopothy

Country Status (9)

Country Link
US (2) US20160289309A1 (enExample)
EP (1) EP3074420A2 (enExample)
JP (1) JP6629201B2 (enExample)
CN (2) CN111569063A (enExample)
BR (1) BR112016010454A2 (enExample)
CA (1) CA2931396C (enExample)
EA (1) EA038994B1 (enExample)
MX (2) MX384909B (enExample)
WO (1) WO2015081085A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
WO2014043480A1 (en) 2012-09-13 2014-03-20 Crystal Ronald G Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
WO2017100632A1 (en) * 2015-12-11 2017-06-15 Arizona Board Of Regents On Behalf Of Arizona State University Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
AR110321A1 (es) 2016-12-07 2019-03-20 Genentech Inc Anticuerpos antitau y métodos de uso
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN110770253A (zh) * 2017-06-16 2020-02-07 百时美施贵宝公司 用于治疗tau蛋白病的组合物和方法
US20190135905A1 (en) * 2017-06-16 2019-05-09 Bristol-Myers Squibb Company Compositions and methods for treating tauopathies
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
GB202010652D0 (en) * 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
CN115607684A (zh) * 2021-07-15 2023-01-17 华中科技大学 一种内耳药物纳米载体及其应用
TW202334201A (zh) * 2021-11-03 2023-09-01 日商衛材R&D企管股份有限公司 抗Ｔａｕ抗體之組成物、劑型及方法
WO2025196217A1 (en) * 2024-03-21 2025-09-25 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5939045A (en) 1994-12-22 1999-08-17 Nissan Chemical Industries, Ltd. Organic bismuth derivatives for X-ray imaging
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
PT939647E (pt) 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
JP2001525470A (ja) 1997-12-12 2001-12-11 マクロメド・インコーポレーテッド タンパク修飾のためのヘテロ官能化星形ポリ（エチレングリコール）
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
CN102348723A (zh) 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
CA3239368A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
AU2010286501B2 (en) * 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
BR112012010587A2 (pt) * 2009-11-06 2015-09-29 David Gladstone Inst métodos e composições para modulação de níveis de tau.
PE20140218A1 (es) * 2010-10-07 2014-03-01 Ac Inmune S A Composicion farmaceutica
SG189174A1 (en) * 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US9518101B2 (en) * 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
DK2885010T3 (da) * 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati

Also Published As

Publication number Publication date
CN111569063A (zh) 2020-08-25
EP3074420A2 (en) 2016-10-05
CN105899230B (zh) 2020-06-09
WO2015081085A3 (en) 2015-08-06
EA038994B1 (ru) 2021-11-18
WO2015081085A2 (en) 2015-06-04
US20200102375A1 (en) 2020-04-02
MX2016006356A (es) 2016-10-28
CN105899230A (zh) 2016-08-24
CA2931396A1 (en) 2015-06-04
JP2017504570A (ja) 2017-02-09
US20160289309A1 (en) 2016-10-06
JP6629201B2 (ja) 2020-01-15
BR112016010454A2 (pt) 2017-12-05
EA201690898A1 (ru) 2016-09-30
MX384909B (es) 2025-03-14
MX2021008755A (es) 2021-08-24

Similar Documents

Publication Publication Date Title
US20200102375A1 (en) Methods of Treating a Tauopathy
AU2020203113B2 (en) Anti-complement C1s antibodies and uses thereof
US20250188192A1 (en) Anti-complement c1s antibodies and uses thereof
US9447180B2 (en) Methods of treating a tauopathy
HK40035696A (en) Methods of treating a tauopathy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191121